AbCellera Biologics Inc.
AbCellera Biologics Inc.（ABCL）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
abcl · 股价预测 · 11 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 11 位华尔街分析师
Buy
11 位分析师
共识
评级分布
12 个月目标价
High
$8.00
Consensus
$7.50
+39.3% upside
Low
$7.00
Median: $7.5 · Last Close: $5.38
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$7.50
39.3% upside
High Target
$8
48.6%
Low Target
$7
30.0%
Current Price
$5.38
as of today
Based on analyst price targets, the ABCL stock price prediction for the next 12 months ranges from $7 to $8. The consensus ABCL price forecast of $7.50 implies 39.3% upside from the current price of $5.38.
短期股价预测
Bull算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.65 | ↑ 5.00% |
1-day model range: $5.58–$5.72. Peak: $5.72 (+5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $3 | -35.7% |
| 2028 | $3 | -48.3% |
| 2029 | $2 | -53.9% |
| 2030 | $2 | -56.6% |
| 2031 | — | -58.0% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ABCL · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-07 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-08-08 | Stifel | Maintains | Buy→Buy |
| 2025-07-14 | Keybanc | Maintains | Overweight→Overweight |
| 2025-05-16 | Truist Securities | Maintains | Buy→Buy |
| 2025-05-09 | Stifel | Maintains | Buy→Buy |
| 2025-04-16 | Keybanc | Maintains | Overweight→Overweight |
| 2025-03-03 | Benchmark | Maintains | Hold→Hold |
| 2025-02-28 | Stifel | Maintains | Buy→Buy |
| 2025-01-08 | Keybanc | Maintains | Overweight→Overweight |
| 2024-11-05 | Stifel | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on AbCellera Biologics Inc. (ABCL) stock. Of the recent 38 rating actions, 1 were upgrades and 2 were downgrades. 11 analysts currently cover ABCL.
分析师推荐趋势
ABCL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$32M
↓ 4.1% YoY
Revenue Next Year
$31M
↓ 3.4% YoY
EPS This Year
$-0.59
EPS Next Year
$-0.64
↑ 9.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast ABCL EPS of $-0.59 for the current fiscal year, based on estimates from 5 analysts. The ABCL revenue forecast is $32M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
ABCL 股价预测由两类独立数据源支撑：来自 11 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。ABCL 的共识目标价为 $7.50（+39.3% 上行空间），分析师共识为 Buy。
ABCL 的短期预测（明日）为 $5.65（+5.00%）。 ABCL 对 2027 年的股价预测均值为 $3。 ABCL 对 2030 年的预测区间为 $2–$3。
AbCellera Biologics Inc. 在 NASDAQ 上市，代码 ABCL。ABCL 在 2027 年的整体展望偏积极，在覆盖分析师中约 82% 对应 Buy 共识。
常见问题
ABCL 预测 · 8 个问题根据 11 位华尔街分析师，ABCL 的 12 个月平均目标价为 $7.50，最高 $8.00、最低 $7.00。若有图表，中位目标价可在上方查看。相对当前价 $5.38，隐含约 +39.3% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.